emsos.org No paid content found

Diagnosis of a bone or soft tissue tumor is a structured process that moves from symptoms and imaging to a tissue sample examined under a microscope. The goal is to determine whether a lesion is benign or malignant, identify its exact type and grade, and stage how far it has spread. Because musculoskeletal tumors are rare and varied, this process is best carried out by a specialized multidisciplinary sarcoma team, as emphasized by the European Musculo-Skeletal Oncology Society (EMSOS), whose stated aims include advancing the science and practice of the diagnosis and treatment of bone and soft tissue tumours.

Why the Diagnostic Process Matters

An accurate diagnosis is the foundation of treatment planning. Benign and malignant lesions can look similar on imaging, and different tumor types respond to very different treatments. A confirmed diagnosis tells the team:

• Whether the lesion is benign, locally aggressive, or malignant
• The specific tumor type (for example, among the many bone and soft tissue tumour entities)
• The grade, which reflects how aggressive the tumor is likely to be
• The stage, meaning whether the disease is localized or has spread

Each of these answers changes what happens next, from simple observation to surgery, chemotherapy, radiotherapy, or a combination.

Step 1: Clinical Assessment

The process usually begins with symptoms. Common reasons a patient seeks care include:

• A persistent or enlarging lump in an arm or leg
• Pain, especially pain that wakes the patient at night or persists at rest
• Swelling or reduced function in a limb
• An incidental finding on an X-ray taken for another reason

The clinician takes a history and performs a physical examination, noting the size, location, consistency, and mobility of any mass, as well as any neurological or vascular symptoms. These findings guide which imaging is requested first.

Step 2: Imaging

Imaging narrows the possibilities and maps the lesion before any tissue is taken.

X-ray

Often the first study for a suspected bone lesion. It shows the location of the abnormality within the bone, the pattern of bone destruction or formation, and features such as periosteal reaction that can suggest whether a process is benign or aggressive.

MRI

Magnetic resonance imaging is central for both bone and soft tissue tumors. It defines the extent of the lesion within the bone and its relationship to surrounding muscles, nerves, and vessels, and it helps plan a biopsy and later surgery.

CT

Computed tomography is useful for assessing cortical bone detail, for certain tumor types, and for staging the chest to check for lung spread, which is a relevant consideration in several musculoskeletal malignancies.

Additional imaging

Bone scans or PET-based imaging may be used to look for other sites of disease. The choice depends on the suspected diagnosis and the staging questions that need answering.

Imaging can strongly suggest a diagnosis, but it cannot confirm the tumor type on its own. That requires tissue.

Step 3: Biopsy

Biopsy obtains a tissue sample for examination by a pathologist and is the step that confirms whether a tumor is benign or malignant and what type it is.

Key points about biopsy in musculoskeletal oncology:

• Planning matters. The biopsy tract is placed so that it can be removed later during definitive surgery, because tumor cells can seed along the tract.
• The right technique is chosen. Options include core needle biopsy, incisional biopsy (removing a piece of the tumor), and excisional biopsy (removing the whole lesion). The choice depends on the lesion's size, location, and suspected type.
• Specialist pathologists are important. Musculoskeletal tumors are rare, and interpretation benefits from a pathologist experienced in bone and soft tissue pathology, sometimes with molecular or genetic testing to refine the diagnosis.

A biopsy performed without proper planning can compromise later treatment, which is one reason referral to a specialized center is recommended before the biopsy is done.

Step 4: Staging and Multidisciplinary Review

Once the diagnosis is confirmed, staging determines how far the disease has spread. This typically includes imaging of the chest and may include other studies depending on the tumor type.

The findings are then reviewed by a multidisciplinary team, which may include orthopedic oncologists, radiologists, pathologists, medical and radiation oncologists, and specialist nurses. This team combines the clinical, imaging, and pathology information to agree on a diagnosis and a treatment plan.

Why Specialized Teams Are Recommended

EMSOS describes its aims as advancing the science and practice of diagnosing and treating bone and soft tissue tumours, promoting basic and clinical research, and disseminating knowledge to provide a common high standard of musculo-skeletal oncology. This reflects a widely recognized principle in the field: because these tumors are rare and their management is complex, outcomes tend to be better when diagnosis and treatment are coordinated by an experienced sarcoma team.

Practical reasons include:

• Correct biopsy planning and technique
• Access to specialist pathology and molecular testing
• Consistent staging and multidisciplinary decision-making
• Treatment plans matched to the specific tumor type and stage

Common Questions

Can imaging alone diagnose a tumor? No. Imaging can suggest whether a lesion is benign or malignant and can guide biopsy, but a tissue sample is needed to confirm the diagnosis.

Does every lump need a biopsy? No. Some lesions have characteristic imaging features that allow observation or a clear benign diagnosis. The decision is made case by case by the treating team.

Why does the biopsy tract matter? Because tumor cells can spread along the tract, it is placed so it can be removed with the tumor during surgery.

What if the diagnosis is unclear after the first biopsy? Additional sampling, specialized pathology review, or molecular testing may be needed. This is one reason specialist centers are recommended.

Bottom Line

Diagnosing a bone or soft tissue tumor combines clinical assessment, imaging (X-ray, MRI, CT, and sometimes other studies), and a carefully planned biopsy interpreted by an experienced pathologist, followed by staging and multidisciplinary review. The process is designed to answer three questions: is it benign or malignant, what type and grade is it, and how far has it spread. Because each answer shapes treatment, having the diagnosis carried out by a specialized musculoskeletal oncology team is a key step toward the best possible outcome.

EMSOS stands for the European Musculo-Skeletal Oncology Society. It is a professional society whose stated aims are to advance the science and practice of diagnosing and treating bone and soft tissue tumours, to promote basic and clinical research, and to disseminate knowledge so that musculo-skeletal oncology can be delivered to a common high standard. If you are a clinician, surgeon, researcher, or trainee working with bone or soft tissue tumours, EMSOS is best understood as a Europe-centred professional network for that field rather than a treatment centre or patient-facing service.

What EMSOS is

The name and mission come directly from the society's own description. Its focus is musculo-skeletal oncology: the branch of medicine concerned with tumours of bone and soft tissue.

Its stated aims break down into three connected purposes:

• Advance science and practice — improve how bone and soft tissue tumours are diagnosed and treated.
• Promote research — support both basic research and clinical research.
• Disseminate knowledge — spread expertise and findings so that care reaches a common high standard.

The phrase "common high standard" is significant. It signals that a core part of the society's purpose is reducing variation in how musculo-skeletal tumours are managed, by sharing knowledge across institutions and countries.

Who it serves

EMSOS is a professional and scientific society, so its audience is the people who diagnose, treat, and study these tumours. That includes:

• Orthopaedic and other surgeons involved in tumour surgery
• Oncologists and other clinicians treating bone and soft tissue tumours
• Pathologists and radiologists contributing to diagnosis
• Basic and clinical researchers in musculo-skeletal oncology
• Trainees and others building expertise in the field

The society's mission is framed around advancing the field and its practitioners, not around providing individual medical advice or patient services.

What it focuses on

The conditions at the centre of EMSOS's work are:

These are the categories named in the society's own description, so they define the scope of its mission rather than a list of specific diseases.

What the society does

EMSOS's activities follow from its three aims. In practical terms, that means:

• Research promotion — encouraging and supporting basic and clinical research in musculo-skeletal oncology.
• Knowledge dissemination — sharing findings and expertise so that standards of diagnosis and treatment improve across the field.
• Standards of care — working toward a common high standard, so that patients are managed according to shared, well-founded practice rather than isolated local habits.

Because the society's stated purpose is to advance science and practice and to disseminate knowledge, its value to the field lies in connecting people and spreading expertise, not in operating as a care provider.

How to engage with EMSOS

If you want to follow or take part in the society's work, the natural starting point is its website at emsos.org, which is the society's own online presence. From there you can learn about the society and its activities directly.

For a clinician or researcher, the practical reasons to engage are:

• Staying current with developments in diagnosing and treating bone and soft tissue tumours
• Connecting with others working in the same specialised field
• Contributing to or following basic and clinical research
• Supporting the goal of a common high standard of musculo-skeletal oncology care

Key takeaways

• EMSOS = European Musculo-Skeletal Oncology Society.
• It is a professional and scientific society, not a treatment service.
• Its mission covers diagnosis and treatment of bone and soft tissue tumours, basic and clinical research, and knowledge dissemination toward a common high standard.
• Its audience is clinicians, surgeons, and researchers in musculo-skeletal oncology.
• The place to follow its work is emsos.org.

Treatment for bone and soft tissue tumours is planned around the specific tumour type, its grade and stage, and where it sits in the body. Most patients are treated by a multidisciplinary team at a specialist sarcoma centre, and the core options are surgery, chemotherapy, radiotherapy, and newer systemic or targeted therapies — often used in combination rather than alone. The sections below explain what each option does, how the sequence is decided, and what to expect during and after treatment.

The main treatment options

Surgery

Surgery is the mainstay of treatment for most bone and soft tissue tumours, and for many patients it is the only treatment needed. The goal is usually wide local excision: removing the tumour together with a margin of normal tissue around it, so that no tumour cells are left behind.

• Limb-sparing surgery removes the tumour while preserving the affected arm or leg. It is possible for many patients and is generally preferred when a safe margin can be achieved.
• Amputation is reserved for tumours where limb-sparing surgery cannot remove the tumour safely, or where the limb would not function afterwards.
• Reconstruction may follow removal of bone: options include metal prostheses, bone grafts, or other implants. The choice depends on the tumour's location, the patient's age, and how much bone was removed.

Chemotherapy

Chemotherapy uses drugs that travel through the bloodstream to kill tumour cells. In musculo-skeletal oncology it is used mainly for:

• Certain bone tumours, such as osteosarcoma and Ewing sarcoma, where it is a standard part of treatment.
• Some high-grade soft tissue sarcomas, particularly those at higher risk of spreading.
• Advanced or metastatic disease, to control tumour growth.

Chemotherapy is usually given as a series of cycles over several months, with rest periods in between.

Radiotherapy

Radiotherapy uses high-energy radiation to damage tumour cells. It is used more often for soft tissue sarcomas than for bone tumours, and can be given:

• Before surgery to shrink a tumour and make it easier to remove.
• After surgery when the margin is close or uncertain, to reduce the risk of local recurrence.
• As the main treatment when surgery is not possible or would cause unacceptable damage.
• For symptom relief in advanced disease.

Targeted and other systemic therapies

Beyond conventional chemotherapy, treatment may include drugs that act on specific molecular features of a tumour, or other systemic agents. Whether these are appropriate depends on the tumour's subtype and biology, and they are typically considered within specialist or trial settings.

How a treatment plan is decided

No single factor determines treatment. The team weighs several things together:

This is why treatment for the same named tumour can differ between two patients.

The role of the multidisciplinary team and specialist centres

A multidisciplinary team (MDT) brings together surgeons, medical and radiation oncologists, radiologists, pathologists, and specialist nurses to agree on a plan. Because these tumours are rare and their treatment is complex, guidance consistently points to management in specialist sarcoma centres, where teams see enough cases to make reliable judgements about margins, reconstruction, and systemic therapy.

The European Musculo-Skeletal Oncology Society (EMSOS) exists to advance the science and practice of diagnosing and treating bone and soft tissue tumours and to promote a common high standard of musculo-skeletal oncology across Europe — a reflection of how central specialist, team-based care is to this field.

Typical treatment sequences

Treatment is often described by where it sits relative to surgery:

• Neoadjuvant therapy — chemotherapy or radiotherapy given before surgery. It may shrink the tumour, make surgery easier, and in some tumours allows the response to treatment to be assessed.
• Adjuvant therapy — chemotherapy or radiotherapy given after surgery to reduce the risk of the tumour returning or spreading.
• Definitive or palliative treatment — when surgery is not the main approach, systemic therapy or radiotherapy may be used to control the disease or relieve symptoms.

Not every patient needs every step. Some are treated with surgery alone; others receive several treatments in sequence.

What to expect during and after treatment

• During treatment, expect regular imaging and clinical reviews to check how the tumour is responding and to catch complications early. Side effects depend on the treatment type and are managed by the care team.
• After treatment, follow-up usually continues for several years, with imaging and clinic visits at intervals. Follow-up looks for recurrence, spread, and late effects of treatment.
• Rehabilitation is often a major part of recovery, especially after limb-sparing surgery or amputation. Physiotherapy and, where needed, prosthetics or occupational therapy help restore function.

Questions to ask your care team

• What type and grade is my tumour, and what stage is it?
• Is surgery possible, and can it be limb-sparing?
• Do I need chemotherapy or radiotherapy, and if so, before or after surgery?
• What are the expected benefits and risks of each option?
• Is my case being discussed by a multidisciplinary team, and is it being managed at a specialist sarcoma centre?
• What follow-up and rehabilitation will I need?

The answers to these questions are what turn a general description of treatment into a plan for a specific patient.

Bone tumors are abnormal growths of tissue within bone. They can be benign (non-cancerous) or malignant (cancerous), and malignant bone tumors are either primary (starting in the bone) or metastatic (spread from cancer elsewhere). Diagnosis typically combines imaging (X-ray, MRI, CT) with a biopsy, and treatment usually involves surgery, and sometimes chemotherapy or radiation, chosen according to tumor type, grade, and stage. If you have persistent bone pain, a visible or palpable lump, or an unexplained fracture, seek medical evaluation; suspected bone cancers are best managed by a specialized musculo-skeletal oncology center such as those represented by EMSOS (European Musculo-Skeletal Oncology Society), whose stated aims are to advance the science and practice of diagnosing and treating bone and soft tissue tumours and to promote a common high standard of care.

Bone tumors vs. soft tissue tumors

The distinction matters because it shapes both diagnosis and treatment:

• Bone tumors arise in bone tissue (including cartilage-forming and bone-forming cells). They are classified as benign or malignant, and malignant ones as primary or metastatic.
• Soft tissue tumors arise in muscle, fat, fibrous tissue, blood vessels, or other non-bone connective tissue.

EMSOS addresses both categories together under "musculo-skeletal tumours," because they share diagnostic methods and are treated by the same multidisciplinary specialty.

Benign vs. malignant, primary vs. metastatic

Many bone lesions found on imaging are benign, but only proper evaluation can distinguish them from malignant tumors.

Symptoms and warning signs

Bone tumors can be silent, especially early. Signs that warrant medical evaluation include:

• Persistent or worsening bone pain, particularly at rest or at night
• A swelling or palpable mass over a bone
• Pain that is not explained by injury or activity
• An unexplained fracture through apparently normal bone (a pathological fracture)
• Systemic symptoms such as unexplained weight loss or fever, which may suggest more widespread disease

These symptoms are non-specific and have many other causes, so they do not by themselves mean cancer. The point is that persistent bone pain or a growing lump should be assessed rather than ignored.

How bone tumors are diagnosed

Diagnosis follows a stepwise pathway. The exact sequence depends on the presentation, but the core elements are:

1. Clinical assessment — history and physical examination, including the site, duration, and character of pain or swelling.
2. Imaging — X-ray is usually first; MRI, CT, and sometimes bone scans or PET are used to characterize the lesion and assess its extent.
3. Biopsy — a tissue sample is taken to establish the diagnosis. Biopsy planning is important because the tract must be placed so it can be removed later during surgery.
4. Staging — determines whether the tumor is localized or has spread, which guides treatment.

Accurate diagnosis generally requires correlation of imaging with pathology, which is why these cases are handled in specialized centers.

How bone tumors are treated

Treatment is chosen according to tumor type, whether it is benign or malignant, its grade and stage, and its location. The main options are:

• Surgery — the primary treatment for most bone tumors, ranging from removal of the lesion to limb-sparing resection or, in some cases, amputation.
• Chemotherapy — used for certain malignant bone tumors, often before and/or after surgery.
• Radiation therapy — used in selected tumors, including some that are not easily resected or are sensitive to radiation.

Benign tumors may only need monitoring or a limited procedure. Malignant tumors usually require a combined approach planned by a multidisciplinary team.

When to seek a specialized center

Because bone tumors are uncommon and their diagnosis and treatment are complex, referral to a specialized musculo-skeletal oncology center is generally recommended when a bone tumor is suspected or confirmed. EMSOS is a European society whose members work in this field, and its stated purpose is to advance diagnosis and treatment, promote research, and disseminate knowledge to provide a common high standard of musculo-skeletal oncology. If you are unsure where to start, ask your physician about referral to a center with expertise in bone and soft tissue tumors.